Halozyme to Acquire Elektrofi: Expanding Innovative Drug Delivery Capabilities and Long-Term Growth

Halozyme Therapeutics has acquired Elektrofi, a biopharmaceutical company with a breakthrough ultra-high concentration microparticle technology for biologics, branded Hypercon. The acquisition expands Halozyme's drug delivery technology offerings and positions the company for long-term revenue growth through Elektrofi's licensing and royalty revenue business model. Initial partner targets include derisked MoAs that are approved blockbusters today, with two partners projected to begin Hypercon formulated product clinical development by year-end 2026. The deal was approved by both companies' Boards of Directors.